Pulmatrix, Inc. – Nasdaq: PULM
Pulmatrix shares have had quite a ride recently. In mid-January PULM, traded on the Nasdaq, were traing below $1. Yesterday they traded over $6 and are now down to $4.87 in early trading on volumes near 10 million – average daily volume is just under three million.
Pulmatrix is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases. Three days ago the company announced that it has entered into a definitive agreement with institutional investors to purchase approximately $5.0 million of shares of common stock in a registered direct offering. That temporarily halted the stock’s rapid rise on dilution worries.
Pulmatrix first reported sales in 2015 and posted a figure of $1.2 million. Since 2011 PULM shares have experienced negative EPS. In 2014 PULM lost $3.47 per share, and in 2015 the company posted an EPS loss of $3.24. No firms or analysts follow shares of PULM.
I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.
|Last Price a/o 11:12 AM EST||$ 13.26|
|Market Cap (mlns)||$ 74.92|
|Shares Outstanding (mlns)||14.69|
|Share Float (mlns)||13.19|
|Short Interest Ratio||0.01|